RAS signaling dysregulation in human embryonal Rhabdomyosarcoma - PubMed (original) (raw)
. 2009 Nov;48(11):975-82.
doi: 10.1002/gcc.20702.
Affiliations
- PMID: 19681119
- DOI: 10.1002/gcc.20702
RAS signaling dysregulation in human embryonal Rhabdomyosarcoma
Simone Martinelli et al. Genes Chromosomes Cancer. 2009 Nov.
Abstract
Rhabdomyosarcoma (RMS) is a common childhood solid tumor, resulting from dysregulation of the skeletal myogenesis program. Two major histological subtypes occur in childhood RMS, embryonal and alveolar. While chromosomal rearrangements account for the majority of alveolar tumors, the genetic defects underlying the pathogenesis of embryonal RMS remain largely undetermined. A few studies performed on small series of embryonal tumors suggest that dysregulation of RAS function may be relevant to disease pathogenesis. To explore further the biological and clinical relevance of mutations with perturbing consequences on RAS signaling in embryonal RMS, we investigated the prevalence of PTPN11, HRAS, KRAS, NRAS, BRAF, MEK1, and MEK2 mutations in a relatively large cohort of primary tumors. While HRAS and KRAS were found to be rarely mutated, we identified somatic NRAS lesions in 20% of cases. All mutations were missense and affected codon 61, with the introduction of a positive charged amino acid residue representing the most common event. PTPN11 was found mutated in one tumor specimen, confirming that somatic defects in this gene are relatively uncommon in RMS, while no mutation was observed in BRAF and MEK genes. Although no clear association of mutations with any clinical variable was observed, comparison of the outcome between mutation-positive and mutation-negative cases indicated a trend for a higher percentage of patients exhibiting a better outcome in the former. Our findings provide evidence that dysregulation of RAS signaling is a major event contributing to embryonal RMS pathogenesis.
Copyright 2009 Wiley-Liss, Inc.
Similar articles
- Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W. Ohashi K, et al. Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2127-33. doi: 10.1073/pnas.1203530109. Epub 2012 Jul 6. Proc Natl Acad Sci U S A. 2012. PMID: 22773810 Free PMC article. - Clinicopathologic and survival correlates of embryonal rhabdomyosarcoma driven by RAS/RAF mutations.
Agaram NP, Huang SC, Tap WD, Wexler LH, Antonescu CR. Agaram NP, et al. Genes Chromosomes Cancer. 2022 Mar;61(3):131-137. doi: 10.1002/gcc.23010. Epub 2021 Nov 16. Genes Chromosomes Cancer. 2022. PMID: 34755412 Free PMC article. - KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, Sandler RS, Kim HJ, Keku TO, Der CJ. Yeh JJ, et al. Mol Cancer Ther. 2009 Apr;8(4):834-43. doi: 10.1158/1535-7163.MCT-08-0972. Mol Cancer Ther. 2009. PMID: 19372556 Free PMC article. - Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X. Quiros RM, et al. Cancer. 2005 Jun 1;103(11):2261-8. doi: 10.1002/cncr.21073. Cancer. 2005. PMID: 15880523 Review. - Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G, Huynh TN, Paller AS. Tran G, et al. J Am Acad Dermatol. 2018 Mar;78(3):579-590.e4. doi: 10.1016/j.jaad.2017.09.022. Epub 2017 Oct 26. J Am Acad Dermatol. 2018. PMID: 29107340 Review.
Cited by
- Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.
Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Liao H, Zhang S, Bogen D, Brohl AS, Sindiri S, Catchpoole D, Badgett T, Getz G, Mora J, Anderson JR, Skapek SX, Barr FG, Meyerson M, Hawkins DS, Khan J. Shern JF, et al. Cancer Discov. 2014 Feb;4(2):216-31. doi: 10.1158/2159-8290.CD-13-0639. Epub 2014 Jan 23. Cancer Discov. 2014. PMID: 24436047 Free PMC article. - Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma.
Rubin BP, Nishijo K, Chen HI, Yi X, Schuetze DP, Pal R, Prajapati SI, Abraham J, Arenkiel BR, Chen QR, Davis S, McCleish AT, Capecchi MR, Michalek JE, Zarzabal LA, Khan J, Yu Z, Parham DM, Barr FG, Meltzer PS, Chen Y, Keller C. Rubin BP, et al. Cancer Cell. 2011 Feb 15;19(2):177-91. doi: 10.1016/j.ccr.2010.12.023. Cancer Cell. 2011. PMID: 21316601 Free PMC article. - A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome.
Owosho AA B Ch D, Huang SC Md, Chen S Mbbs, Kashikar S Dds, Estilo CL Dmd, Wolden SL Md, Wexler LH Md, Huryn JM Dds, Antonescu CR Md. Owosho AA B Ch D, et al. Oral Oncol. 2016 Oct;61:89-97. doi: 10.1016/j.oraloncology.2016.08.017. Epub 2016 Sep 6. Oral Oncol. 2016. PMID: 27688110 Free PMC article. - Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells.
Blum JM, Añó L, Li Z, Van Mater D, Bennett BD, Sachdeva M, Lagutina I, Zhang M, Mito JK, Dodd LG, Cardona DM, Dodd RD, Williams N, Ma Y, Lepper C, Linardic CM, Mukherjee S, Grosveld GC, Fan CM, Kirsch DG. Blum JM, et al. Cell Rep. 2013 Nov 27;5(4):933-40. doi: 10.1016/j.celrep.2013.10.020. Epub 2013 Nov 14. Cell Rep. 2013. PMID: 24239359 Free PMC article. - Non-coding RNA in rhabdomyosarcoma progression and metastasis.
Ramadan F, Saab R, Hussein N, Clézardin P, Cohen PA, Ghayad SE. Ramadan F, et al. Front Oncol. 2022 Aug 11;12:971174. doi: 10.3389/fonc.2022.971174. eCollection 2022. Front Oncol. 2022. PMID: 36033507 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous